Skip to main content

ORIGINAL RESEARCH article

Front. Genet.
Sec. Cancer Genetics and Oncogenomics
Volume 15 - 2024 | doi: 10.3389/fgene.2024.1458047
This article is part of the Research Topic Genetic and Immunological Insights in Solid Tumors: Comprehensive Approaches to Treatment View all articles

Title：Immune Regulation and Prognostic Prediction Model Establishment and Validation of PSMB6 in Lung Adenocarcinoma

Provisionally accepted
Haiyang Zhao Haiyang Zhao 1Kexin Luo Kexin Luo 1Meihan Lui Meihan Lui 2Yuanze Cai Yuanze Cai 3Siman Liu Siman Liu 3Shijuan Li Shijuan Li 4Yongsheng Zhao Yongsheng Zhao 1*Hongpan Zhang Hongpan Zhang 2*
  • 1 Department of Thoracic Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan, Hebei Province, China
  • 2 Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
  • 3 North Sichuan Medical College, Nanchong, Sichuan Province, China
  • 4 Nanchong Central Hospital, Nanchong, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Lung cancer is one of the most common malignant tumors, and patients are often diagnosed at an advanced stage, posing a substantial risk to human health, so it is crucial to establish a model to forecast the prognosis of patients with lung cancer. Recent research has indicated that proteasome 20S subunit 6 (PSMB6) may be closely associated with anti-apoptotic pathways, and proliferation transduction signals in tumor cells of different tumors. However, the precise role of PSMB6 in the immunoregulatory processes within lung adenocarcinoma (LUAD) is yet to be elucidated. By analyzing the TCGA database, we discovered a positive correlation between the expression of PSMB6 and tumor growth trends, and lung adenocarcinoma patients with elevated PSMB6 expression levels had a worse prognosis. Our findings suggest a close correlation between PSMB6 expression levels, immune cell infiltration and immune checkpoint gene expression, which suggests that PSMB6 may become a new independent prognostic indicator. In addition, we developed a prognostic model of PSMB6-regulated immune infiltration-associated genes by analyzing the link between PSMB6 and the immune microenvironment. This model can not only predict the prognosis of lung adenocarcinoma but also forecasts the patient's reaction to immunotherapy. The validity of this research outcome has been confirmed by the GSE31210 and IMvigor210 cohorts. Analysis of the Kaplan-Meier Plotter database indicates that individuals with elevated levels of PSMB6 expression exhibit a poorer prognosis. Additionally, in vitro experiments demonstrated that knockdown of PSMB6 inhibits the proliferation, migration, and invasion of lung adenocarcinoma cells while promoting their apoptosis. Overall, our findings suggest that PSMB6 could remarkably influence the management and treatment of lung adenocarcinoma, opening new avenues for targeted immunotherapeutic strategies.

    Keywords: Lung Adenocarcinoma, PSMB6, Immunotherapy, Immune infiltration, Tumor immune microenvironment

    Received: 01 Jul 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Zhao, Luo, Lui, Cai, Liu, Li, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yongsheng Zhao, Department of Thoracic Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan, 063000, Hebei Province, China
    Hongpan Zhang, Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.